ODDB.org: Open Drug Database | Drugs

Home - HMG CoA reductase inhibitors, other combinations (C10BX)

C10BX - Lipid Modifying Agents in Combination with Other Drugs

ATC-DDD Version 2016. Source: WHO

C - Cardiovascular System

This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.

C10 - Lipid Modifying Agents

The DDDs are based on the treatment of hypercholesterolemia.

C10B - Lipid Modifying Agents, Combinations

Fixed combinations of blood glucose-lowering drugs and lipid modifying agents are classified in A10B.

For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.

C10BX - Lipid Modifying Agents in Combination with Other Drugs

This group comprises products which contain lipid modifying agents (including combinations of various lipid modifying agents) in combination with other substances.
Combinations with e.g. ACE inhibitors, angiotensin II antagonists, calcium channel blockers or diuretics are classified in C10BX.

The DDD for the fixed combination of rosuvastatin and valsartan is 1 UD (1 tablet), regardless of strength.

2024	©ywesee GmbH